Jun. 5 at 2:28 PM
Citizens reiterated
$ALT Market Outperform-
$25 and said, "Altimmune's (ALT, MO,
$25 PT) pemvidutide will be featured in an oral presentation on Saturday
(6/22) highlighting cardio-inflammatory lipidomic analyses."
$MDGL $IVA $VKTX ALGS
$AKRO ETNB
Citizens added, "While the abstract remains under embargo until June 13,
$ALT has previously presented data showing pemvidutide reduced lipid species associated with systemic inflammation and CV disease in obese, non-diabetics.
$ALT will present three posters on pemvidutide, focusing on its effectiveness in reducing visceral adipose tissue mass, its impact on cardiovascular risk, and its role in reverse cholesterol transport.
The next key catalyst for
$ALT shares is the Phase 2b
IMPACT data in #MASH coming sometime this month."
